Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MK-7655A in Pediatric Gram-negative Infections
NCT03230916Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of imipenem + cilastatin + relebactam in Gram-negative bacterial infection, sponsored by Merck & Co. Primary endpoints: Imipenem Area Under the Concentration Time Curve From Time 0 to Infinity, Imipenem Maximum Concentration and 13 more. Started Nov 2017; status: completed.
02
Drugs
imipenem + cilastatin + relebactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT03230916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230916.